Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner: Potential role of ET-1

Medicine & Life Sciences

• Linagliptin 89%
• Pathologic Neovascularization 77%
• Endothelin-1 59%
• Blood Glucose 45%
• Bosentan 29%
• fluorescein isothiocyanate dextran 9%
• Endothelin A Receptors 9%
• Dipeptidyl-Peptidase IV Inhibitors 9%
• Angiogenesis Inhibitors 8%
• Blood Vessels 8%
• Metformin 7%
• Animals 6%
• Brain 6%
• Confocal Microscopy 6%
• In Vitro Techniques 6%
• Wistar Rats 5%
• Cell Movement 5%
• Endothelial Cells 5%
• Glucose 4%

Chemical Compounds

• Linagliptin 100%
• Endothelin-1 82%
• Bosentan 42%
• Angiogenic 23%
• Dipeptidyl Peptidase IV Inhibitor 12%
• Glycemic 12%
• Metformin 11%
• Retinal 9%
• Confocal Microscopy 8%
• Agent Interacting With Transmitter, Hormone or Drug Receptor 8%
• Glucose 5%
• Volume 4%
• Surface 2%